1. Clinical & Scientific Overview
Clindamycin Hydrochloride / Phosphate (TIP-MED-000149, Reference Code [8.21]) is classified under
Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Lincosamide 50S Ribosomal Inhibitor & Bacterial Toxin Suppressor (Schedule H | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.21], p. 103): Dalacin C (Pfizer), Clindac (Galderma), Clincin, Vaginal Ovules: Clingen / Candid-CL — Strengths & Dosage Forms: Capsules: 150 mg, 300 mg; IV/IM Injection: 150 mg/mL (300 mg/2mL, 600 mg/4mL); Topical Acne Gel: 1%; Vaginal Ovules: 100 mg
Capsules: 150 mg, 300 mg; IV/IM Injection: 150 mg/mL (300 mg/2mL, 600 mg/4mL); Topical Acne Gel: 1%; Vaginal Ovules: 100 mg
3. Mechanism of Action & Pharmacodynamics
Lincosamide 50S Ribosomal Inhibitor & Bacterial Toxin Suppressor (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08): clinical efficacy is mediated via Lincosamide 50S Ribosomal Inhibitor & Bacterial Toxin Suppressor (Schedule H | NLEM 2022) for Odontogenic / severe dental abscess, skin and soft-tissue infections (including CA-MRSA and necrotising fasciitis / streptococcal toxic shock syndrome alongside Penicillin!), diabetic foot osteomyelitis, pelvic inflammatory disease / bacterial vaginosis.
4. Therapeutic Indications & Evidence-Supported Uses
- Odontogenic / severe dental abscess, skin and soft-tissue infections (including CA-MRSA and necrotising fasciitis / streptococcal toxic shock syndrome alongside Penicillin!), diabetic foot osteomyelitis, pelvic inflammatory disease / bacterial vaginosis
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adults: 150–300 mg (up to 450 mg) PO TDS–QID (every 6–8 hours); IV: 600–900 mg IV q8h (Children: 20–40 mg/kg/day in 3–4 doses)
Administration & Meal Timing: MANDATORY ADMINISTRATION RULE: Swallow capsules whole with a FULL 250 mL GLASS OF WATER while sitting/standing UPRIGHT, and remain upright for AT LEAST 30 MINUTES (prevents caustic pill oesophagitis!) | Every 6 to 8 Hours (TDS or QID)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal & Hepatic: Hepatobiliary elimination — no dose adjustment needed in renal failure; extend interval in severe Child–Pugh C hepatic failure
Renal & Hepatic: Hepatobiliary elimination — no dose adjustment needed in renal failure; extend interval in severe Child–Pugh C hepatic failure
Renal & Hepatic: Hepatobiliary elimination — no dose adjustment needed in renal failure; extend interval in severe Child–Pugh C hepatic failure
7. Contraindications, Precautions & High-Risk Warnings
- BOXED WARNING — CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHOEA (CDAD): Clindamycin carries one of the highest risks of severe/fatal pseudomembranous colitis (during or up to 2 months after therapy!). Contraindicated in history of ulcerative colitis or antibiotic-associated colitis
Key Clinical Precautions: Renal & Hepatic: Hepatobiliary elimination — no dose adjustment needed in renal failure; extend interval in severe Child–Pugh C hepatic failure
8. Adverse Effects Profile
- Diarrhoea (up to 20%), abdominal pain, nausea, metallic taste, maculopapular rash, oesophagitis
- Severe C. difficile colitis (profuse watery/mucoid/bloody diarrhoea, fever, abdominal cramps -> STOP Clindamycin immediately and treat with Oral Vancomycin 125 mg QID!), SJS/TEN/DRESS, hepatotoxicity
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Antagonistic with Macrolides (Erythromycin/Clarithromycin) and Linezolid (overlapping 50S ribosomal binding sites — never combine!); enhances neuromuscular blockade of Vecuronium/Rocuronium
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: TWO CRITICAL COUNTER RULES: (1) Swallow Dalacin C capsule with a full glass of water while sitting upright and do NOT lie down for 30 minutes (prevents throat burns); (2) If you develop persistent watery or bloody diarrhoea (even weeks after finishing), stop the medicine, do NOT take Imodium, and see your doctor immediately
- Meal & Clock Timing Instruction: MANDATORY ADMINISTRATION RULE: Swallow capsules whole with a FULL 250 mL GLASS OF WATER while sitting/standing UPRIGHT, and remain upright for AT LEAST 30 MINUTES (prevents caustic pill oesophagitis!) (Every 6 to 8 Hours (TDS or QID))
- Missed Dose Protocol: Take as soon as remembered unless within 2h of next dose
- Geriatric Dispensing Pearl: High risk of severe C. difficile colitis in older adults >=65 years (especially if also taking a PPI!)
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Capsules: 150 mg, 300 mg; IV/IM Injection: 150 mg/mL (300 mg/2mL, 600 mg/4mL); Topical Acne Gel: 1%; Vaginal Ovules: 100 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.21] (p. 103)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.19]-C62 Ertapenem — Broad-Spectrum Parenteral Carbapenem Beta-Lactam Antibiotics — IC
- [8.19]-C63 Imipenem + Cilastatin [FDC] — Broad-Spectrum Parenteral Carbapenem Beta-Lactam Antibiotics — IC
- [8.20]-C64 Erythromycin — Macrolide 50S Ribosomal Protein Synthesis Inhibitors — Potent CYP
- [8.23]-C65 Gentamicin Sulfate — Aminoglycoside 30S Ribosomal Bactericidal Antibiotics (Schedule H
